AFWM
NTLA icon

Abich Financial Wealth Management’s Intellia Therapeutics NTLA Stock Holding History

Abich Financial Wealth Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$4.79K Buy
233
+161
+224% +$3.71K 0.01% 261
2024
Q2 		$1.61K Buy
72
+66
+1,100% +$1.57K ﹤0.01% 518
2024
Q1 		$165 Buy
+6
New +$167 ﹤0.01% 497

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Abich Financial Wealth Management's NTLA Position: Q3 2024 in Review

Abich Financial Wealth Management increased its Intellia Therapeutics (NTLA) stake by 224% in Q3 2024, buying an estimated $3.71K and bringing the position to 233 shares worth $4.79K. The position accounts for 0.01% of the portfolio, ranked #261.

Abich Financial Wealth Management first reported a position in NTLA in Q1 2024 and has held it in 3 quarters since. 283 funds tracked by Wall St. Rank hold NTLA as of Q3 2024.

  • Abich Financial Wealth Management held 233 shares of Intellia Therapeutics worth $4.79K as of Q3 2024.
  • Abich Financial Wealth Management bought 161 Intellia Therapeutics shares in Q3 2024, an estimated $3.71K.
  • Intellia Therapeutics made up 0.01% of Abich Financial Wealth Management's portfolio in Q3 2024, its #261 holding.
  • Abich Financial Wealth Management first reported a position in Intellia Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • 283 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2024.

Based on Abich Financial Wealth Management's 13F filing for Q3 2024, filed 25 Oct 2024.